Compare Peloton Interactive Inc (PTON) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Repligen Corporation Common Stock — how do they compare? Peloton Interactive Inc trades at $5.04 (market cap $2.30B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 4.8× Peloton Interactive Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Repligen Corporation Common Stock for 0 Days on average.
| PTON | RGEN | |
|---|---|---|
Market Cap | $2.30B | $11.14B |
Volume | 9,511,173 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $194.57 |
52-Week Low | $3.71 | $102.87 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $2.80B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $5.06, down 1.56% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company achieved its first profitable year in 2026 with $63M net income, though Q3 2026 earnings are pending. Revenue declined from $3.6B in 2022 to $2.4B in 2026, but profitability improved significantly with net margin turning positive. Recent product launches include new treadmills and AI features, signaling ongoing turnaround efforts.
PTON presents a speculative opportunity with analyst consensus price target of $8.00 (58% upside) and 50% buy ratings. Key risks include declining subscriber counts, high debt levels, and competitive pressures. The stock's valuation appears reasonable with P/S of 0.93, but negative shareholder equity and volatile cash flow history warrant caution. Near-term catalyst will be Q3 2026 earnings results versus expectations of $0.1098 EPS.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
